Please use this identifier to cite or link to this item:
http://doi.org/10.25358/openscience-7720Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Helmstädter, Johanna | - |
| dc.contributor.author | Keppeler, Karin | - |
| dc.contributor.author | Küster, Leonie | - |
| dc.contributor.author | Münzel, Thomas | - |
| dc.contributor.author | Daiber, Andreas | - |
| dc.contributor.author | Steven, Sebastian | - |
| dc.date.accessioned | 2022-09-12T09:46:10Z | - |
| dc.date.available | 2022-09-12T09:46:10Z | - |
| dc.date.issued | 2022 | - |
| dc.identifier.uri | https://openscience.ub.uni-mainz.de/handle/20.500.12030/7735 | - |
| dc.description.abstract | Cardiovascular outcome trials revealed cardiovascular benefits for type 2 diabetes mellitus patients when treated with long-acting glucagon-like peptide-1 (GLP-1) receptor agonists. In the last decade, major advances were made characterising the physiological effects of GLP-1 and its action on numerous targets including brain, liver, kidney, heart and blood vessels. However, the effects of GLP-1 and receptor agonists, and the GLP-1 receptor on the cardiovascular system have not been fully elucidated. We compare results from cardiovascular outcome trials of GLP-1 receptor agonists and review pleiotropic clinical and preclinical data concerning cardiovascular protection beyond glycaemic control. We address current knowledge on GLP-1 and receptor agonist actions on the heart, vasculature, inflammatory cells and platelets, and discuss evidence for GLP-1 receptor-dependent versus independent effects secondary of GLP-1 metabolites. We conclude that the favourable cardiovascular profile of GLP-1 receptor agonists might expand their therapeutic use for treating cardiovascular disease even in non-diabetic populations. | en_GB |
| dc.language.iso | eng | de |
| dc.rights | CC BY-NC-ND | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
| dc.subject.ddc | 610 Medizin | de_DE |
| dc.subject.ddc | 610 Medical sciences | en_GB |
| dc.title | Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits : the role of the GLP-1 receptor | en_GB |
| dc.type | Zeitschriftenaufsatz | de |
| dc.identifier.doi | http://doi.org/10.25358/openscience-7720 | - |
| jgu.type.dinitype | article | en_GB |
| jgu.type.version | Published version | de |
| jgu.type.resource | Text | de |
| jgu.organisation.department | FB 04 Medizin | de |
| jgu.organisation.number | 2700 | - |
| jgu.organisation.name | Johannes Gutenberg-Universität Mainz | - |
| jgu.rights.accessrights | openAccess | - |
| jgu.journal.title | British journal of pharmacology | de |
| jgu.journal.volume | 179 | de |
| jgu.journal.issue | 4 | de |
| jgu.pages.start | 659 | de |
| jgu.pages.end | 676 | de |
| jgu.publisher.year | 2022 | - |
| jgu.publisher.name | Wiley | de |
| jgu.publisher.place | Malden, MA | de |
| jgu.publisher.issn | 1476-5381 | de |
| jgu.organisation.place | Mainz | - |
| jgu.subject.ddccode | 610 | de |
| jgu.publisher.doi | 10.1111/bph.15462 | de |
| jgu.organisation.ror | https://ror.org/023b0x485 | - |
| Appears in collections: | JGU-Publikationen | |
Files in This Item:
| File | Description | Size | Format | ||
|---|---|---|---|---|---|
 | glucagonlike_peptide1_glp1_re-20220905115559788.pdf | 2.7 MB | Adobe PDF | View/Open |